Exact Sciences reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard Esophagus test that is currently in development for the detection of esophageal adenocarcinoma – EAC –
Exact Sciences reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard Esophagus test that is currently in development for the detection of esophageal adenocarcinoma – EAC –
The 5 Best Healthcare stocks to buy in March 2024 have gained bullish reviews from Wall Street analysts. The healthcare sector in the U.S. is one of the largest employers
Bullish option flow detected in EXACT Sciences with 2,848 calls trading, 1.4x expected, and implied vol increasing over 6 points to 74.61%. Apr-24 95 calls and Apr-24 62.5 calls are
Evercore ISI analyst Vijay Kumar is adding Exact Sciences to the firm’s “Tactical Outperform” list, noting that the stock has underperformed, falling 20% year-to-date, which the firm sees as largely
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exact Sciences (EXAS – Research Report) and Geron (GERN – Research Report) with bullish sentiments.
Exact Sciences (EXAS)
In a report issued on March 14, Puneet Souda from Leerink Partners maintained a Buy rating on Exact Sciences. The company’s shares closed last Monday at $58.86, close to its 52-week low of $56.05.
According to TipRanks.com, Souda is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Exact Sciences with a $89.00 average price target, representing a 52.9% upside. In a report issued on March 14, Canaccord Genuity also maintained a Buy rating on the stock with a $90.00 price target.
See today’s best-performing stocks on TipRanks >>
Geron (GERN)
Robert W. Baird analyst Joel Beatty maintained a Buy rating on Geron on March 14 and set a price target of $4.50. The company’s shares closed last Monday at $3.18.
According to TipRanks.com, Beatty is a 5-star analyst with an average return of
Geron has an analyst consensus of Strong Buy, with a price target consensus of $5.08, which is a 51.6% upside from current levels. In a report issued on February 28, Needham also maintained a Buy rating on the stock with a $4.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EXAS: